Saruparib shows favorable activity, safety in mutant advanced solid tumors.- AstraZeneca
Treatment with saruparib (AZD5305) demonstrated encouraging efficacy, favorable safety, a wide therapeutic index, and improved pharmacokinetic properties compared with currently approved PARP inhibitors in patients with advanced solid tumors harboring BRCA1/2, PALB2, or RAD51C/D mutations, according to findings from the phase 1/IIa PETRA study (NCT04644068) presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting.